Zhejiang Medicine Co Ltd (600216) - Net Assets
Based on the latest financial reports, Zhejiang Medicine Co Ltd (600216) has net assets worth CN¥11.21 Billion CNY (≈ $1.64 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.14 Billion ≈ $2.07 Billion USD) and total liabilities (CN¥2.92 Billion ≈ $427.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Zhejiang Medicine Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥11.21 Billion |
| % of Total Assets | 79.31% |
| Annual Growth Rate | 14.16% |
| 5-Year Change | 35.34% |
| 10-Year Change | 64.29% |
| Growth Volatility | 25.93 |
Zhejiang Medicine Co Ltd - Net Assets Trend (1997–2024)
This chart illustrates how Zhejiang Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Zhejiang Medicine Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Zhejiang Medicine Co Ltd (1997–2024)
The table below shows the annual net assets of Zhejiang Medicine Co Ltd from 1997 to 2024. For live valuation and market cap data, see market cap of Zhejiang Medicine Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥10.87 Billion ≈ $1.59 Billion |
+8.83% |
| 2023-12-31 | CN¥9.99 Billion ≈ $1.46 Billion |
+2.85% |
| 2022-12-31 | CN¥9.71 Billion ≈ $1.42 Billion |
+5.75% |
| 2021-12-31 | CN¥9.18 Billion ≈ $1.34 Billion |
+14.35% |
| 2020-12-31 | CN¥8.03 Billion ≈ $1.18 Billion |
-2.69% |
| 2019-12-31 | CN¥8.25 Billion ≈ $1.21 Billion |
+2.08% |
| 2018-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
+3.92% |
| 2017-12-31 | CN¥7.78 Billion ≈ $1.14 Billion |
+11.26% |
| 2016-12-31 | CN¥6.99 Billion ≈ $1.02 Billion |
+5.69% |
| 2015-12-31 | CN¥6.62 Billion ≈ $968.00 Million |
+0.81% |
| 2014-12-31 | CN¥6.56 Billion ≈ $960.18 Million |
+1.25% |
| 2013-12-31 | CN¥6.48 Billion ≈ $948.29 Million |
+4.57% |
| 2012-12-31 | CN¥6.20 Billion ≈ $906.81 Million |
+40.83% |
| 2011-12-31 | CN¥4.40 Billion ≈ $643.92 Million |
+13.90% |
| 2010-12-31 | CN¥3.86 Billion ≈ $565.33 Million |
+35.02% |
| 2009-12-31 | CN¥2.86 Billion ≈ $418.70 Million |
+57.89% |
| 2008-12-31 | CN¥1.81 Billion ≈ $265.19 Million |
+107.42% |
| 2007-12-31 | CN¥873.73 Million ≈ $127.85 Million |
+12.40% |
| 2006-12-31 | CN¥777.31 Million ≈ $113.74 Million |
+6.16% |
| 2005-12-31 | CN¥732.23 Million ≈ $107.15 Million |
+13.40% |
| 2004-12-31 | CN¥645.68 Million ≈ $94.48 Million |
+2.74% |
| 2003-12-31 | CN¥628.48 Million ≈ $91.97 Million |
-0.20% |
| 2002-12-31 | CN¥629.71 Million ≈ $92.15 Million |
+3.49% |
| 2001-12-31 | CN¥608.50 Million ≈ $89.04 Million |
-4.18% |
| 2000-12-31 | CN¥635.03 Million ≈ $92.92 Million |
+1.59% |
| 1999-12-31 | CN¥625.07 Million ≈ $91.47 Million |
+79.30% |
| 1998-12-31 | CN¥348.61 Million ≈ $51.01 Million |
+14.61% |
| 1997-12-31 | CN¥304.17 Million ≈ $44.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 21269.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥5.93 Billion | 55.72% |
| Common Stock | CN¥961.64 Million | 9.03% |
| Other Comprehensive Income | CN¥2.70 Billion | 25.32% |
| Other Components | CN¥1.06 Billion | 9.93% |
| Total Equity | CN¥10.65 Billion | 100.00% |
Zhejiang Medicine Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Medicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BRP Inc
TO:DOO
|
$2.02 Billion |
|
Zhejiang Yonghe Refrigerant Co Ltd
SHG:605020
|
$2.02 Billion |
|
Shenzhen Rongda Photosensitive & Technology Co Ltd
SHE:300576
|
$2.02 Billion |
|
Ceconomy AG
XETRA:CEC
|
$2.02 Billion |
|
Visual Photonics Epitaxy Co Ltd
TW:2455
|
$2.02 Billion |
|
Spartan Resources Ltd
AU:SPR
|
$2.01 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
$2.01 Billion |
|
Hunan Boyun New Materials Co Ltd
SHE:002297
|
$2.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Medicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,630,715,541 to 10,648,142,085, a change of 1,017,426,544 (10.6%).
- Net income of 1,160,510,673 contributed positively to equity growth.
- Dividend payments of 142,577,037 reduced retained earnings.
- Share repurchases of 29,001,735 reduced equity.
- Other comprehensive income increased equity by 2,690,319,823.
- Other factors decreased equity by 2,661,825,180.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.16 Billion | +10.9% |
| Dividends Paid | CN¥142.58 Million | -1.34% |
| Share Repurchases | CN¥29.00 Million | -0.27% |
| Other Comprehensive Income | CN¥2.69 Billion | +25.27% |
| Other Changes | CN¥-2.66 Billion | -25.0% |
| Total Change | CN¥- | 10.56% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 38.02x to 1.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CN¥0.38 | CN¥14.33 | x |
| 1998-12-31 | CN¥0.43 | CN¥14.33 | x |
| 1999-12-31 | CN¥0.77 | CN¥14.33 | x |
| 2000-12-31 | CN¥0.79 | CN¥14.33 | x |
| 2001-12-31 | CN¥0.75 | CN¥14.33 | x |
| 2002-12-31 | CN¥0.77 | CN¥14.33 | x |
| 2003-12-31 | CN¥0.78 | CN¥14.33 | x |
| 2004-12-31 | CN¥0.80 | CN¥14.33 | x |
| 2005-12-31 | CN¥0.90 | CN¥14.33 | x |
| 2006-12-31 | CN¥0.95 | CN¥14.33 | x |
| 2007-12-31 | CN¥1.11 | CN¥14.33 | x |
| 2008-12-31 | CN¥2.22 | CN¥14.33 | x |
| 2009-12-31 | CN¥3.52 | CN¥14.33 | x |
| 2010-12-31 | CN¥4.75 | CN¥14.33 | x |
| 2011-12-31 | CN¥5.42 | CN¥14.33 | x |
| 2012-12-31 | CN¥7.29 | CN¥14.33 | x |
| 2013-12-31 | CN¥6.86 | CN¥14.33 | x |
| 2014-12-31 | CN¥6.93 | CN¥14.33 | x |
| 2015-12-31 | CN¥6.93 | CN¥14.33 | x |
| 2016-12-31 | CN¥7.44 | CN¥14.33 | x |
| 2017-12-31 | CN¥7.77 | CN¥14.33 | x |
| 2018-12-31 | CN¥7.97 | CN¥14.33 | x |
| 2019-12-31 | CN¥8.20 | CN¥14.33 | x |
| 2020-12-31 | CN¥8.01 | CN¥14.33 | x |
| 2021-12-31 | CN¥9.16 | CN¥14.33 | x |
| 2022-12-31 | CN¥9.66 | CN¥14.33 | x |
| 2023-12-31 | CN¥10.09 | CN¥14.33 | x |
| 2024-12-31 | CN¥11.10 | CN¥14.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.90%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.38%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.30x
- Recent ROE (10.90%) is above the historical average (10.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 12.22% | 4.05% | 0.97x | 3.12x | CN¥6.73 Million |
| 1998 | 10.45% | 3.27% | 0.97x | 3.30x | CN¥1.53 Million |
| 1999 | 5.36% | 2.80% | 0.69x | 2.78x | CN¥-28.75 Million |
| 2000 | 1.29% | 0.76% | 0.75x | 2.27x | CN¥-55.19 Million |
| 2001 | 2.73% | 1.89% | 0.55x | 2.61x | CN¥-43.61 Million |
| 2002 | 3.03% | 1.68% | 0.68x | 2.64x | CN¥-43.17 Million |
| 2003 | 0.92% | 0.51% | 0.68x | 2.67x | CN¥-56.69 Million |
| 2004 | 1.99% | 0.92% | 0.75x | 2.87x | CN¥-51.29 Million |
| 2005 | 11.27% | 4.33% | 0.85x | 3.05x | CN¥9.18 Million |
| 2006 | 7.59% | 2.66% | 0.87x | 3.28x | CN¥-18.60 Million |
| 2007 | 6.51% | 2.56% | 0.78x | 3.27x | CN¥-30.30 Million |
| 2008 | 54.05% | 25.86% | 1.15x | 1.81x | CN¥792.68 Million |
| 2009 | 42.60% | 29.01% | 1.08x | 1.36x | CN¥928.84 Million |
| 2010 | 29.68% | 25.11% | 0.98x | 1.20x | CN¥758.99 Million |
| 2011 | 23.06% | 20.98% | 0.93x | 1.18x | CN¥573.39 Million |
| 2012 | 13.72% | 16.12% | 0.75x | 1.14x | CN¥229.90 Million |
| 2013 | 7.00% | 9.16% | 0.65x | 1.17x | CN¥-193.72 Million |
| 2014 | 2.60% | 3.51% | 0.61x | 1.20x | CN¥-484.09 Million |
| 2015 | 2.45% | 3.60% | 0.55x | 1.25x | CN¥-497.73 Million |
| 2016 | 6.45% | 8.53% | 0.60x | 1.26x | CN¥-247.72 Million |
| 2017 | 3.47% | 4.45% | 0.58x | 1.34x | CN¥-475.78 Million |
| 2018 | 4.77% | 5.32% | 0.68x | 1.31x | CN¥-400.13 Million |
| 2019 | 4.36% | 4.87% | 0.68x | 1.32x | CN¥-443.31 Million |
| 2020 | 9.35% | 9.79% | 0.70x | 1.37x | CN¥-50.06 Million |
| 2021 | 11.91% | 11.45% | 0.73x | 1.43x | CN¥167.41 Million |
| 2022 | 5.83% | 6.65% | 0.65x | 1.34x | CN¥-386.42 Million |
| 2023 | 4.46% | 5.51% | 0.61x | 1.33x | CN¥-533.43 Million |
| 2024 | 10.90% | 12.38% | 0.68x | 1.30x | CN¥95.70 Million |
Industry Comparison
This section compares Zhejiang Medicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,691,234,838
- Average return on equity (ROE) among peers: 6.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Medicine Co Ltd (600216) | CN¥11.21 Billion | 12.22% | 0.26x | $2.02 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $903.62 Million | 4.28% | 2.45x | $1.16 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $441.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.87 Billion | 20.71% | 0.25x | $5.01 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.80 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $3.04 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $9.03 Billion | 25.71% | 0.43x | $13.75 Billion |
| Hainan Haiyao Co Ltd (000566) | $275.57 Million | 17.28% | 1.12x | $947.33 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $389.67 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.29 Billion | 2.31% | 2.07x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.32 Billion |
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition produ… Read more